Abstract Library

#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors

Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Genc C, Falconi M, Partelli S, Muffatti F, Van Eeden S,

Keywords: Neuroendocrine tumors, pancreas, recurrence, survival, Ki-67 proliferation index, prognosis,

#1677 A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors.

Introduction: Surgical resection is the preferred treatment for NF-pNET, however recurrence still occurs frequently after curative surgery, worsening prognosis of patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Genc C

Authors: Genc C, Jilesen A, Partelli S, Falconi M, Muffatti F,

Keywords: pNET, recurrence, predictive-model.,

#1639 Endoscopic Ultrasound Appearance of Pancreatic Serotonin-Staining Neuroendocrine Neoplasms: A Case Series

Introduction: The pancreatic localization of serotonin-staining neuroendocrine neoplasms (serotoninomas) is extremely rare. Less than 350 cases have been reported in the world literature.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Massironi S

Authors: Massironi S, Partelli S, Petrone M, Conte D, Falconi M,

Keywords: pNEN,

#1241 Health-Related Quality of Life in Patients after Diagnosis of Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms (PNEN) <= 2 cm

Introduction: Pancreatic neuroendocrine neoplasms (pNEN) <=2 cm can be treated conservatively.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Maurizi A

Authors: Maurizi A, Partelli S, Pezzilli R, Crippa S, Falconi M,

Keywords: pNEN, quality of life,

#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment

Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Falconi M, Spada F,

Keywords: pancreatic neuroendocrine tumor, synchronous liver metastases, debulking, resection, prognostic factors, survival,